

**THE EFFECT OF ARABINOSE 1,5-BISPHOSPHATE ON RAT HEPATIC  
6-PHOSPHOFRUCTO-1-KINASE AND FRUCTOSE-1,6-BISPHOSPHATASE**

Simon J. Pilkis\*, Molly M. McGrane\*\*, Paul D. Kountz\*\*, M. Raafat El-Maghrabi\*,  
Jo Pilkis\*, Bruce E. Maryanoff<sup>§</sup>, Allen B. Reitz<sup>§</sup>, and Stephen J. Benkovic<sup>†</sup>

\*Department of Physiology and Biophysics, State University of New York,  
School of Medicine, Stony Brook, New York 11794

\*\*Department of Molecular Physiology and Biophysics,  
Vanderbilt University School of Medicine, Nashville, Tennessee 37232

<sup>§</sup>Chemical Research Department, McNeil Pharmaceutical,  
Spring House, Pennsylvania 19477

<sup>†</sup>Department of Chemistry, The Pennsylvania State University,  
University Park, Pennsylvania 16802

Received May 29, 1986

---

**Summary.** The  $\alpha$ - and  $\beta$ -anomers of arabinose 1,5-bisphosphate and ribose 1,5-bisphosphate were tested as effectors of rat liver 6-phosphofructo-1-kinase and fructose-1,6-bisphosphatase. Both anomers of arabinose 1,5-bisphosphate activated the kinase and inhibited the bisphosphatase. The  $\alpha$ -anomer was the more effective kinase activator while the  $\beta$ -anomer was the more potent inhibitor of the bisphosphatase. Inhibition of the bisphosphatase by both anomers was competitive, and both potentiated allosteric inhibition by AMP.  $\beta$ -Arabinose 1,5-bisphosphate was also more effective in decreasing fructose 2,6-bisphosphate binding to the enzyme. Neither anomer of ribose 1,5-bisphosphate affected 6-phosphofructo-1-kinase or fructose-1,6-bisphosphatase, indicating that the configuration of the C-2 (C-3 in Fru 2,6-P<sub>2</sub>) hydroxyl group is important for biological activity. These results are also consistent with arabinose 1,5-bisphosphate binding to the active site and thereby enhancing the interaction of AMP with the allosteric site. © 1986 Academic Press, Inc.

---

Fructose 2,6-bisphosphate (Fru 2,6-P<sub>2</sub>)<sup>1</sup> is an important regulator of hepatic carbohydrate metabolism. It activates 6-PF-1-K and inhibits Fru-1,6-P<sub>2</sub>ase (1-3). The mechanism whereby Fru 2,6-P<sub>2</sub> inhibits rat liver Fru-1,6-P<sub>2</sub>ase has been the subject of some controversy. Since Fru 2,6-P<sub>2</sub> potentiates allosteric inhibition by AMP and induces a sigmoidal substrate concentration dependence, François et al. (4) postulated that Fru 2,6-P<sub>2</sub> must bind to an allosteric site rather than interact with the catalytic site. However, based on kinetic (5-9),

---

<sup>1</sup>**Abbreviations used:** arabinose 1,5-P<sub>2</sub>, arabinose 1,5-bisphosphate; Fru 1,6-P<sub>2</sub>, fructose 1,6-bisphosphate; Fru-1,6-P<sub>2</sub>ase, fructose-1,6-bisphosphatase; Fru 2,6-P<sub>2</sub>, fructose 2,6-bisphosphate; Fru 6-P, fructose 6-phosphate; 6-PF-1-K, 6-phosphofructo-1-kinase; P<sub>i</sub>, inorganic phosphate; ribose 1,5-P<sub>2</sub>, ribose 1,5-bisphosphate.

protein modification (6,10), ligand binding (11), and spectroscopic studies (12,13), others have proposed that Fru 2,6-P<sub>2</sub> binds to the catalytic site. Also, it has been suggested that the sugar bisphosphate interacts with both the catalytic and allosteric sites (14). The Fru 2,6-P<sub>2</sub>-induced sigmoidal substrate concentration dependence may also be explained by a "ligand exclusion" phenomenon (9) at the active site. Recently, Maryanoff et al. (15) reported the synthesis of  $\alpha$ - and  $\beta$ -arabinose 1,5-P<sub>2</sub> and briefly mentioned their activation of rat liver 6-PF-1-K and inhibition of rat liver Fru-1,6-P<sub>2</sub>ase. The object of this work is to characterize further the effects of the arabinose 1,5-P<sub>2</sub> compounds in an attempt to elucidate the site of Fru 2,6-P<sub>2</sub> interaction with Fru-1,6-P<sub>2</sub>ase.

### MATERIALS AND METHODS

**Materials.** ATP, Fru 6-P, and Fru 2,6-P<sub>2</sub> were obtained from Sigma Chemical Company. [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> was prepared by a modification (16) of the method of El-Maghrabi et al. (17). [1-<sup>32</sup>P]Fru 1,6-P<sub>2</sub> was prepared as in Pilkis et al. (5).  $\alpha$ - and  $\beta$ -arabinose 1,5-P<sub>2</sub> were synthesized as described by Maryanoff et al. (15)<sup>2</sup>.  $\alpha$ - and  $\beta$ -ribose 1,5-P<sub>2</sub> were prepared by related methods, which will be described elsewhere (18)<sup>3</sup>.

**Enzyme Purifications and Assays.** Rat liver 6-PF-1-K was purified to homogeneity by the method of Pilkis et al. (19) and was assayed spectrophotometrically as previously described (19). Homogeneous rat liver Fru-1,6-P<sub>2</sub>ase was prepared as described by Riou et al. (20). It was assayed either spectrophotometrically as previously described (20) or by measuring <sup>32</sup>P<sub>i</sub> release from [1-<sup>32</sup>P]Fru 1,6-P<sub>2</sub> as described by Pilkis et al. (5).

**Rate of Dialysis Measurements of Sugar Bisphosphate Binding to Fructose-1,6-bisphosphatase.** A modification of the procedure of McGrane et al. (11) was used. Fru-1,6-P<sub>2</sub>ase and [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> were placed in the upper chamber of a microdialysis cell where the contents were stirred continuously with a small stirring bar. Buffer was pumped continuously through the lower chamber, and after 2 min a steady state was achieved such that the rate of entrance of [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> into the lower chamber by dialysis and exit by flow were equal. Thus, the concentration in the effluent may be assumed from Fick's law to be proportional to the free [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> concentrations. Aliquots of increasing concentrations of  $\alpha$ - or  $\beta$ -arabinose 1,5-P<sub>2</sub> were added to the enzyme solution in the upper chamber and [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> was counted in fractions of the effluent from the lower chamber. Each experiment resulted in a series of values of free and bound [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> as estimated according to Colowick and Womack (21).

### RESULTS

**Effect of Arabinose 1,5-P<sub>2</sub> and Ribose 1,5-P<sub>2</sub> on Rat Liver 6-PF-1-K and Fru-1,6-P<sub>2</sub>ase Activities.** The ability of the  $\alpha$ - and  $\beta$ -anomers of

---

<sup>2</sup>Please note that these substances were not 100% isomerically pure: the  $\alpha$  isomer contained 85-90% of that isomer, and the  $\beta$  isomer contained nearly 95% of that isomer.

<sup>3</sup>The  $\beta$ -ribose 1,5-P<sub>2</sub> was >95% isomerically pure; the sample of  $\alpha$ -ribose 1,5-P<sub>2</sub> contained 75%  $\alpha$  isomer and 25%  $\beta$  isomer. Complete characterization (elemental analysis; <sup>1</sup>H and <sup>13</sup>C NMR) has been performed.




Figure 1. Activation of rat liver 6-PF-1-K by  $\alpha$ - and  $\beta$ -arabinose-1,5- $P_2$  and ribose 1,5- $P_2$ . Enzyme activity was measured spectrophotometrically as described in Methods. Activity is expressed as the ratio of the rate measured with 0.2 mM Fru 6-P to that measured with 4 mM Fru 6-P. The structures of each compound are shown as inserts:  $\beta$ -Fru 2,6- $P_2$  ( $\bullet$ ),  $\alpha$ -arabinose 1,5- $P_2$  ( $\Delta$ ),  $\beta$ -arabinose 1,5- $P_2$  ( $\triangle$ ), and  $\alpha$ - or  $\beta$ -ribose 1,5- $P_2$  ( $\blacksquare$ ).

arabinose 1,5- $P_2$  to activate 6-PF-1-K is shown in Fig. 1. The  $\alpha$ -anomer of arabinose 1,5- $P_2$  ( $K_A = 0.5 \mu M$ ) was slightly more effective than the  $\beta$ -anomer ( $K_A = 1 \mu M$ ). Both compounds, however, had substantially higher  $K_A$ 's for activation than Fru 2,6- $P_2$  ( $K_A = 0.02 \mu M$ ). Ribose 1,5- $P_2$  is structurally identical to arabinose 1,5- $P_2$  except for the configuration of the C-2 hydroxyl group. However, neither the  $\alpha$ - nor  $\beta$ -anomer of ribose 1,5- $P_2$  activated 6-PF-1-K when tested at concentrations up to 100  $\mu M$  (Fig. 1, and data not shown).

The effects of  $\alpha$ - and  $\beta$ -arabinose 1,5- $P_2$  on rat liver Fru-1,6- $P_2$ ase were also tested (Fig. 2). The  $\beta$ -anomer was a potent competitive inhibitor of Fru-1,6- $P_2$ ase with a  $K_i$  of 3.5  $\mu M$ . The  $\alpha$ -anomer was also a competitive inhibitor, but with a  $K_i$  of 20-30  $\mu M$ . For comparison, the  $K_i$  for Fru 2,6- $P_2$  is about 0.2  $\mu M$  (5, and data not shown). Thus, while both arabinose 1,5- $P_2$  anomers are reasonable inhibitors, they are still only 1/10-1/20th as potent as Fru 2,6- $P_2$ . Unlike Fru 2,6- $P_2$ , however, neither anomer of arabinose 1,5- $P_2$  induced sigmoidicity in the substrate dependence of Fru-1,6- $P_2$ ase, even at high concentrations (Fig. 2 and data not shown). These findings suggest that the specificity of Fru-1,6- $P_2$ ase includes preference for the two phosphate moieties




Figure 2. Inhibition of rat liver Fru-1,6-P<sub>2</sub>ase by  $\alpha$ - and  $\beta$ -arabinose-1,5-P<sub>2</sub>. Enzyme activity was measured by the <sup>32</sup>P<sub>i</sub> release assay as described in Methods. Dixon plots of (A)  $\alpha$ - ( $\alpha$ -A15P<sub>2</sub>) and (B)  $\beta$ -arabinose 1,5-P<sub>2</sub> ( $\beta$ -A15P<sub>2</sub>) inhibition of Fru-1,6-P<sub>2</sub>ase. The enzyme concentration was 1.2 nM and Fru 1,6-P<sub>2</sub> concentrations were (●) 2  $\mu$ M, (■) 3  $\mu$ M, (▲) 5  $\mu$ M, (◆) 10  $\mu$ M, (○) 20  $\mu$ M, and (□) 50  $\mu$ M.

in the *cis* configuration (c.f.,  $\beta$ -Fru 2,6-P<sub>2</sub> and  $\beta$ -arabinose 1,5-P<sub>2</sub>), in contrast to 6-PF-1-K activation which shows little stereochemical preference. Neither  $\alpha$ - nor  $\beta$ -ribose 1,5-P<sub>2</sub> had any inhibitory effect on Fru-1,6-P<sub>2</sub>ase (data not shown), just as they had no effect on 6-PF-1-K.

#### Effect of Arabinose 1,5-P<sub>2</sub> on AMP Inhibition of Fru-1,6-P<sub>2</sub>ase.

It has been argued that, since Fru 2,6-P<sub>2</sub> potentiates AMP inhibition of Fru-1,6-P<sub>2</sub>ase, the sugar bisphosphate must bind to a separate and distinct allosteric site (4). A corollary to this hypothesis is that a purely competitive inhibitor of the enzyme, which binds only to the active site, would not alter AMP inhibition. Thus, the presence of such an effect on AMP inhibition by a competitive inhibitor would discount the argument that Fru 2,6-P<sub>2</sub> must necessarily bind to an allosteric site. Fig. 3 shows that, in the absence of any effectors, AMP inhibited Fru-1,6-P<sub>2</sub>ase with an  $I_{0.5}$  of about 42  $\mu$ M, while in the presence of 3  $\mu$ M  $\beta$ -arabinose 1,5-P<sub>2</sub> the  $I_{0.5}$  was decreased to 14  $\mu$ M. Thus,




Figure 3. Potentiation of AMP inhibition of Fru-1,6-P<sub>2</sub>ase by  $\beta$ -arabinose 1,5-P<sub>2</sub>. Enzyme activity was measured by the <sup>32</sup>P<sub>i</sub> release assay as described in Methods. Activity is expressed as the percent of control. The concentration of Fru 1,6-P<sub>2</sub> was 2  $\mu$ M.

the  $\beta$ -anomer of arabinose 1,5-P<sub>2</sub> which interacts with the active site can also potentiate AMP inhibition. The  $\alpha$ -anomer also potentiated AMP inhibition, but 20 to 30-fold higher concentrations were necessary. In the presence of 1  $\mu$ M Fru 2,6-P<sub>2</sub> the  $I_{0.5}$  for AMP inhibition was decreased to 12  $\mu$ M (data not shown).

Effect of Temperature on  $K_m$  for Substrate and Inhibition by Arabinose 1,5-P<sub>2</sub> of Fru-1,6-P<sub>2</sub>ase. François et al. found that the effects of Fru 2,6-P<sub>2</sub> and AMP on Fru-1,6-P<sub>2</sub>ase vary with temperature in a similar manner, while the  $K_m$  for Fru 1,6-P<sub>2</sub> and the  $I_{0.5}$  for a substrate analog ([ $\alpha$ + $\beta$ ]methyl-Fru 1,6-P<sub>2</sub>) did not change with temperature (4). They argued that these findings suggest that Fru 2,6-P<sub>2</sub> does not interact at the active site. We re-examined the effect of temperature on the  $K_m$  of Fru-1,6-P<sub>2</sub>ase and on inhibition by arabinose 1,5-P<sub>2</sub>. As shown in Table I, when the temperature is increased from 15 to 45°C, not only does the  $K_m$  increase from 1.6 to 4.4  $\mu$ M but the  $I_{0.5}$  for arabinose 1,5-P<sub>2</sub> also increases from 4.5 to 16  $\mu$ M. These results are in sharp contrast to those of François et al. (4) and provide more evidence that arabinose 1,5-P<sub>2</sub> interacts at the active site of Fru-1,6-P<sub>2</sub>ase.

Effect of Arabinose 1,5-P<sub>2</sub> on Fru 2,6-P<sub>2</sub> Binding to Fru-1,6-P<sub>2</sub>ase. It has been shown that Fru 2,6-P<sub>2</sub> binds to Fru-1,6-P<sub>2</sub>ase to the extent of 1 mole per mole of enzyme subunit (11). If Fru 2,6-P<sub>2</sub> binds to the active site, it would be expected that a competitive inhibitor would compete for this binding. Fig. 4 illustrates the effect of arabinose 1,5-P<sub>2</sub> upon [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> binding. A

TABLE I

EFFECT OF TEMPERATURE ON  $K_m$  FOR SUBSTRATE AND INHIBITION  
BY  $\beta$ -ARABINOSE 1,5-BISPHOSPHATE OF FRUCTOSE-1,6-BISPHOSPHATASE

Temperature	$K_m$ Fru 1,6-P <sub>2</sub>	$I_{0.5}$ $\beta$ -Arabinose 1,5-P <sub>2</sub>
15°	1.6 $\mu$ M	4.5 $\mu$ M
30°	3.0 $\mu$ M	6.8 $\mu$ M
45°	4.4 $\mu$ M	16.0 $\mu$ M

NOTE: Fru-1,6-P<sub>2</sub>ase activity was assayed spectrophotometrically as described in Methods.  $I_{0.5}$  is defined as the concentration of  $\beta$ -arabinose 1,5-P<sub>2</sub> which gives 50% inhibition at 5  $\mu$ M Fru 1,6-P<sub>2</sub>.

half-maximal decrease in binding was exhibited at 10  $\mu$ M  $\beta$ -arabinose 1,5-P<sub>2</sub>, and 100  $\mu$ M  $\beta$ -arabinose 1,5-P<sub>2</sub> completely abolished Fru 2,6-P<sub>2</sub> binding. Furthermore,  $\alpha$ -arabinose-1,5-P<sub>2</sub> was a less potent inhibitor of Fru 2,6-P<sub>2</sub> binding than the  $\beta$ -anomer; as indicated in Fig. 4, a half-maximal decrease in binding required 80  $\mu$ M  $\alpha$ -arabinose 1,5-P<sub>2</sub>. Thus, inhibition of Fru 2,6-P<sub>2</sub> binding exhibited the same anomeric specificity as the inhibition of catalytic activity, providing




Figure 4. Effect of  $\alpha$ - and  $\beta$ -arabinose 1,5-P<sub>2</sub> upon Fru 2,6-P<sub>2</sub> binding to rat liver Fru-1,6-P<sub>2</sub>ase. Binding of [2-<sup>32</sup>P]Fru 2,6-P<sub>2</sub> (F2,6-P<sub>2</sub>) to Fru-1,6-P<sub>2</sub>ase was measured by the rate of dialysis technique (11,21). The enzyme concentration was 1.5  $\mu$ M, the Fru 2,6-P<sub>2</sub> concentration was 10  $\mu$ M, and the increasing arabinose 1,5-P<sub>2</sub> concentrations were as indicated in the figure.

persuasive evidence that Fru 2,6-P<sub>2</sub> is indeed binding at the active site of the Fru-1,6-P<sub>2</sub>ase.

### DISCUSSION

Both anomers of arabinose 1,5-P<sub>2</sub> are less potent effectors than Fru 2,6-P<sub>2</sub>, indicating that the 1-hydroxymethyl group of  $\beta$ -Fru 2,6-P<sub>2</sub>, though important, is not essential for activation of 6-PF-1-K or inhibition of Fru-1,6-P<sub>2</sub>ase.  $\beta$ -Arabinose 1,5-P<sub>2</sub> was a much more potent inhibitor of Fru-1,6-P<sub>2</sub>ase than the  $\alpha$ -anomer. Consistent with this finding is evidence indicating that Fru-1,6-P<sub>2</sub>ase acts only on the  $\alpha$ -anomer of Fru 1,6-P<sub>2</sub> (22) (i.e., the anomer in which the phosphate moieties are in the *cis* configuration). The lack of any effect of  $\alpha$ - or  $\beta$ -ribose 1,5-P<sub>2</sub> on either 6-PF-1-K or Fru-1,6-P<sub>2</sub>ase activity suggests that the configuration of the C-2 (C-3 in Fru 2,6-P<sub>2</sub>) hydroxyl group is important. Although Rose and Warms (23) reported that ribose 1,5-P<sub>2</sub> was a potent activator of erythrocyte 6-PF-1-K, no definite evidence for the identity, composition, or purity of this putative ribose 1,5-P<sub>2</sub> was provided, and it is uncertain that the activating agent was actually ribose 1,5-P<sub>2</sub>.

A number of groups have studied the mechanism of Fru 2,6-P<sub>2</sub> potentiation of the inhibition of Fru-1,6-P<sub>2</sub>ase by AMP (8,10,11). Binding studies demonstrated that Fru 2,6-P<sub>2</sub> enhances the affinity of the enzyme for AMP (11). The sensitivity of Fru-1,6-P<sub>2</sub>ase to AMP inhibition is also increased by the substrate, Fru 1,6-P<sub>2</sub>, which enhances AMP binding (11). These results suggest that Fru 2,6-P<sub>2</sub> and Fru 1,6-P<sub>2</sub> both bind to the active site and bring about a conformational change that facilitates AMP binding. Moreover, Fru 2,6-P<sub>2</sub> binding at the active site might induce a conformational change in the enzyme similar to that induced by AMP interaction with the allosteric site. Compatible with this hypothesis is the finding that Fru 2,6-P<sub>2</sub> and AMP both induce UV-difference spectra with saturable absorbance maxima at the same wavelengths (6,11). NMR and EPR studies are consistent with this hypothesis since they indicate that the catalytic site and the AMP binding sites are in close proximity to one another (24). Recently, <sup>1</sup>H and <sup>31</sup>P NMR studies also suggested that Fru 2,6-P<sub>2</sub> affects the interaction of AMP with Fru-1,6-P<sub>2</sub>ase by interacting with the active site (12,13). In this vein, the present study shows that arabinose 1,5-P<sub>2</sub> is a purely competitive inhibitor of the bisphosphatase and

competitively decreases Fru 2,6-P<sub>2</sub> binding to the enzyme, while potentiating AMP inhibition. The observation that interaction of substate and substrate analogs with the active site can potentiate allosteric behavior is intriguing and, in the case of Fru-1,6-P<sub>2</sub>ase, is more consistent with the "ligand exclusion" hypothesis (9,25) than with a classic active versus allosteric site model.

#### REFERENCES

1. Claus, T.H., El-Maghrabi, M.R., Regen, D.M., Stewart, H.B., McGrane, M., Kountz, P.D., Nyfeler, F., Pilkis, J., and Pilkis, S.J. (1984) *Curr. Top. Cell. Reg.* **23**, 57-86.
2. Uyeda, M.K., Furuya, E., Richards, C.S., and Yokoyama, M. (1982) *Mol. Cell. Biochem.* **48**, 97-120.
3. Pilkis, S.J., El-Maghrabi, M.R., McGrane, M., Pilkis, J., Fox, E., and Claus, T.H. (1982) *Mol. Cell. Endocrinol.* **25**, 245-266.
4. François, J., Van Schaftingen, E., and Hers, H.-G. (1983) *Eur. J. Biochem.* **134**, 269-275.
5. Pilkis, S.J., El-Maghrabi, M.R., Pilkis, J., and Claus, T.H. (1981) *J. Biol. Chem.* **256**, 3619-3622.
6. Pilkis, S.J., El-Maghrabi, M.R., McGrane, M., Pilkis, J., and Claus, T.H. (1981) *J. Biol. Chem.* **256**, 11489-11495.
7. Pontremoli, S., Melloni, E., Michetti, M., Salamino, F., Sparatore, B., and Horecker, B.L. (1982) *Arch. Biochem. Biophys.* **218**, 609-613.
8. Ganson, N.J., and Fromm, H. (1982) *Biochem. Biophys. Res. Commun.* **108**, 233-240.
9. Marcus, F., Edelstein, I., and Rittenhouse, J. (1984) *Biochem. Biophys. Res. Commun.* **119**, 1103-1108.
10. Gottschalk, M.E., Chattey, T., Edelstein, I., and Marcus, F. (1982) *J. Biol. Chem.* **257**, 8016-8020.
11. McGrane, M., El-Maghrabi, M.R., and Pilkis, S.J. (1983) *J. Biol. Chem.* **258**, 10445-10454.
12. Ganson, N.J., and Fromm, H.J. (1985) *J. Biol. Chem.* **260**, 2837-2843.
13. Scheffler, J.E., and Fromm, H.J. (1986) *Fed. Proc.* **45**, 1868.
14. Meek, D.N. and Nimmo, H.G. (1983) *FEBS Lett.* **160**, 105-109.
15. Maryanoff, B.E., Reitz, A.B., Tutwiler, G.F., Benkovic, S.J., Benkovic, P.A., and Pilkis, S.J. (1984) *J. Am. Chem. Soc.* **106**, 7851-7853.
16. Stewart, H.B., El-Maghrabi, M.R., and Pilkis, S.J. (1985) *J. Biol. Chem.* **260**, 12935-12941.
17. El-Maghrabi, M.R., Claus, T.H., Pilkis, J., Fox, E. and Pilkis, S.J. (1982) *J. Biol. Chem.* **257**, 7603-7607.
18. Maryanoff, B.E., Reitz, A.B., and Nortey, S.O. McNeil  
Pharmaceutical, Manuscript in preparation.
19. Pilkis, S.J., El-Maghrabi, M.R., and Claus, T.H. (1982) *Arch. Biochem. Biophys.* **215**, 379-385.
20. Riou, J.P., Claus, T.H., Flockhart, D.A., Corbin, J.D., and Pilkis, S.J. (1977) *Proc. Natl. Acad. Sci. USA* **74**, 4615-4619.
21. Colowick, S.P., and Womack, F.C. (1969) *J. Biol. Chem.* **244**, 774-777.
22. Benkovic, P.A., Bullard, W.P., DeMaine, M., Fishbein, R., Schray, K.J., Steffens, J.J., and Benkovic, S.J. (1974) *J. Biol. Chem.* **249**, 930-931.
23. Rose, I.A., and Warms, J.V.B. (1974) *Biochem. Biophys. Res. Commun.* **59**, 1333-1340.
24. Cunningham, B.A., Raushel, F.M., Villafranca, J.J., and Benkovic, S.J. (1981) *Biochemistry* **20**, 359-362.
25. Fisher, H.F., Gates, R.E., and Cross, D.G. (1970) *Nature (London)* **228**, 247-249.